secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001104659-26-027037
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor FY2025 net loss $105M; Deramiocel PDUFA date Aug 22, 2026
------------------------------------------------------------------

- Net loss of $30.2M in Q4 2025 ($0.62/sh) and $105.0M for FY2025 ($2.26/sh).
- Revenue was $0 in Q4 and FY2025, vs $11.1M and $22.3M in prior-year periods, as Nippon Shinyaku milestones fully recognized.
- Cash, equivalents and marketable securities $318.1M at Dec 31, 2025, up from $151.5M; expected to fund operations through 2027.
- BLA for Deramiocel in Duchenne muscular dystrophy under FDA review; PDUFA target date August 22, 2026.
- Phase 3 HOPE-3 trial met primary endpoint (PUL v2.0, p=0.03) and key cardiac endpoint (LVEF, p=0.04).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/0001104659-26-027037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/capr-20260312x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-027037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer